RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies
New partnership delivers clinically proven products and manufacturing processes for advanced therapies
SEATTLE, Aug. 16, 2022 — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.
10 International Scientists Nominated For The $100,000 Stem Cell SpaceShot Grant
Bordeaux, France / August 30th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the nomination of 10 international scientists for the Stem Cell SpaceShot grant. Each nominee was anonymously selected based on a 1-page research project description. In early October, the 10 nominees will be interviewed by an international jury of experts in stem cell biology, gene editing and biophysics, which will determine the winner of the $100,000 Stem Cell SpaceShot Grant. [Read more…]
Ageless Biotech Signs Agreement with Simon Med Imaging of Scottsdale, AZ, One of the Nation’s Largest Siemens 3 Tesla MRI 3D Scan Outpatient Providers, to Advance Its FDA Approved IND Trial
SHERIDAN, Wyo., Aug. 23, 2022 — Ageless Biotech (ABT), Inc., a biotech company created to bring Stem Cell-based Therapeutics to market, is excited to have Simon Med Imaging, one of the major players within the healthcare and biotech research fields, helping to advance its U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND) for the treatment of Osteoarthritis of the Knee. [Read more…]
Overcoming major challenges in cardiac drug discovery using human induced pluripotent stem cell technology
Highlights
- The biggest opportunity for success in cardiac drug discovery and development is to make these processes more efficient and affordable, since they carry relatively higher risk of clinical trial failure compared to other disciplines.
- Human iPSC technology is increasingly utilized to develop disease models that reliably mimic the diversity of patient pathogenicity and disease severity in vitro.
- Phenotypic screening based on iPSC-derived disease models is making cardiac drug discovery more time and cost effective by enabling target-agnostic studies and increasing the translational power of early drug discovery outcomes.
- « Previous Page
- 1
- …
- 138
- 139
- 140
- 141
- 142
- …
- 334
- Next Page »